• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by DBV Technologies S.A.

    6/3/26 4:05:31 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DBVT alert in real time by email
    8-K
    00-0000000 true --12-31 0001613780 false 0001613780 2026-06-03 2026-06-03 0001613780 us-gaap:CommonStockMember 2026-06-03 2026-06-03 0001613780 dei:AdrMember 2026-06-03 2026-06-03
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    June 3, 2026

    Date of Report (Date of earliest event reported)

     

     

    DBV Technologies S.A.

    (Exact name of registrant as specified in its charter)

     

     

     

    France   001-36697   Not applicable
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    107 avenue de la République
    92320 Châtillon France
      Not Applicable
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: +33 1 55 42 78 78

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Ordinary shares, nominal value €0.10 per share   n/a   The Nasdaq Stock Market LLC*
    American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share   DBVT   The Nasdaq Stock Market LLC

     

    *

    Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On June 3, 2026, in connection with the shareholder vote at the Annual General Meeting (as defined below), the shareholders of the Company amended the Company’s bylaws (statuts), effective immediately.

    Articles 18 and 21 of the bylaws have been modified to comply with the provisions of French law decree nº2026-94 of February 13, 2026, regarding the Ordinary Share Record Date. Article 15 of the bylaws has been amended to set the age limit for the Chief Executive Officer at 70 years, providing that no person aged 70 or over may be appointed as Chief Executive Officer and that, when such age limit is reached during the term of office, the duties of the Chief Executive Officer shall automatically cease at the end of the Ordinary General Meeting of Shareholders convened to approve the financial statements for the financial year in which the Chief Executive Officer reaches the age limit.

    The foregoing description is qualified in its entirety by reference to the full text of the bylaws, the English translation of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On June 3, 2026, the Company held its Annual Combined Meeting of Shareholders (“Annual General Meeting”). At the Annual General Meeting, the Company’s shareholders voted on the thirty-nine proposals set forth below. The voting results with respect to each matter voted upon at the Annual General Meeting are set forth below. A more detailed description of each proposal is set forth in the Company’s Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026.

    Within the authority of the Ordinary Shareholders’ Meeting:

     

    1.

    The resolution approving the annual financial statements for the year ended December 31, 2025 was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    190,121,468   499,104   109,298

     

    2.

    The resolution approving the consolidated financial statements for the year ended December 31, 2025 was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    190,120,075   499,182   110,613

     

    3.

    The resolution allocating income for the year ended December 31, 2025 was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    190,083,191   517,230   129,449

     

    4.

    The resolution allocating the accumulated deficit to the “Additional paid-in capital” was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    189,903,938   686,203   139,729

     

    5.

    The resolution regarding the statutory auditors’ special report on regulated agreements was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    189,953,469   643,692   132,709


    6.

    The resolution regarding the renewal of the term of office of KPMG, as statutory auditor, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    190,030,444   559,162   140,264

     

    7.

    The resolution ratifying the provisional appointment of Ms. Philina Lee, as director, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    189,933,070   576,503   220,297

     

    8.

    The resolution renewing Mr. Michael J. Goller, as director, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    184,088,474   6,434,694   206,702

     

    9.

    The resolution renewing Mr. Daniel Tassé, as director, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    189,963,580   572,553   193,737

     

    10.

    The resolution renewing Ms. Maïlys Ferrère, as director, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    184,843,380   5,679,732   206,758

     

    11.

    The resolution approving the information set out in section I of Article L.22-10-9 of the French Commercial Code on the compensation of corporate officers for the year ended December 31, 2025 was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    186,194,144   4,392,687   143,039

     

    12.

    The resolution approving the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Michel de Rosen, Chairman of the Board of Directors, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    189,809,255   745,457   175,158

     

    13.

    The resolution approving the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Daniel Tassé, Chief Executive Officer, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,542,147   27,019,628   168,095

     

    14.

    The resolution regarding the advisory opinion on the compensation of named executive officers other than the Chief Executive Officer was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,642,700   26,944,966   142,204


    15.

    The resolution regarding the increase of the total remuneration (annual budget) allocated to Directors was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    189,507,135   1,133,707   89,028

     

    16.

    The resolution approving the compensation policy for the Chairman of the Board of Directors for the year ending December 31, 2026, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,853,126   26,746,610   130,134

     

    17.

    The resolution approving the compensation policy for the Directors for the year ending December 31, 2026, was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,712,437   26,888,763   128,670

     

    18.

    The resolution approving the compensation policy for the Chief Executive Officer and Deputy Chief Executive Officer for the year ending December 31, 2026 was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,659,650   26,938,208   132,012

     

    19.

    The resolution authorizing the Board of Directors to buy back company shares on the Company’s behalf pursuant to Article L.22-10-62 of the French Commercial Code was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    190,044,199   578,978   106,693

    Within the authority of the Extraordinary Shareholders’ Meeting:

     

    20.

    The resolution delegating to the Board of Directors to reduce the share capital by cancellation of shares pursuant to Article L.22-10-62 of the French Commercial Code was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    178,709,924   11,905,250   114,696

     

    21.

    The resolution delegating authority to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares with preferential subscription rights was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,957,492   26,604,297   168,081

     

    22.

    The resolution delegating authority to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities, and/or securities giving access to equity securities to be issued, without preferential subscription rights by means of a public offer excluding the offers set out in paragraph 1 of Article L.411-2 of the French Monetary and Financial Code, and/or as consideration for securities in the context of a public exchange offer was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,540,160   27,013,589   176,121


    23.

    The resolution delegating authority to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities, and/or securities giving access to equity securities to be issued, without preferential subscription rights by means of a public offer referred to in paragraph 1 of Article L.411-2 of the French Monetary and Financial Code was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,511,162   27,041,733   176,975

     

    24.

    The resolution delegating powers to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares, without preferential subscription rights in favor of one or more persons specifically designated by the Board of Directors was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,479,331   27,045,946   204,593

     

    25.

    The resolution delegating authority to the Board of Directors to issue ordinary shares, giving, as the case may be, access to ordinary shares or the allocation of debt securities (of the Company or a group company) and/or securities giving access to ordinary shares (of the Company or a group company), without preferential subscription rights in favor of a category of persons satisfying determined characteristics was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,482,259   27,043,570   204,041

     

    26.

    The resolution delegating authority to the Board of Directors to decide on the issue of ordinary shares to be issued immediately or in the future by the Company, without preferential subscription rights in favor of a category of persons satisfying determined characteristics within the framework of an equity financing agreement on the United States stock market known as “At-The-Market” or “ATM Program” was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,591,321   26,997,592   140,957

     

    27.

    The resolution delegating authority to the Board of Directors to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription rights, in the event of excess demand was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,648,862   26,941,679   139,329

     

    28.

    The resolution delegating to the Board of Directors to increase the share capital by issuance of ordinary shares and/or securities giving access to the share capital within the limits set by the applicable legal and regulatory provisions on the date of the capital increase in consideration for contributions in kind of securities or securities giving access to the share capital was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,704,689   26,896,892   128,289

     

    29.

    The resolution delegating authority to the Board of Directors to decide on any merger-absorption, spin-off or partial contribution of assets was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    151,575,334   38,969,127   185,409


    30.

    The resolution delegating authority to the Board of Directors to issue ordinary shares giving, as the case may be, access to ordinary shares or to the allocation of debt securities (of the Company or of a group company), and/or securities giving access to ordinary shares (of the Company or of a group company), in the context of a merger, spin-off or partial contribution of assets decided by the Board of Directors pursuant to the delegation referred to in the twenty-ninth resolution was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    173,977,797   16,563,371   188,702

     

    31.

    The resolution regarding the overall limit on the maximum authorized amounts set under the twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-eighth and thirtieth resolutions was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    189,934,713   641,446   153,711

     

    32.

    The resolution delegating authority to the Board of Directors to increase the capital by means of the incorporation of reserves, profits and/or premiums was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    188,531,612   2,064,866   133,392

     

    33.

    The resolution delegating authority to the Board of Directors to increase the capital by the issue of ordinary shares and/or securities giving access to the share capital, without preferential subscription rights in favor of the members of a company savings plan pursuant to Articles L.3332-18 and seq. of the French Labor Code was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    181,766,144   8,830,270   133,456

     

    34.

    The resolution delegating authority to the Board of Directors to issue warrants (BSA), subscription and/or acquisition of new and/or existing warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable warrants (BSAAR) without preferential subscription rights in favor of a category of persons was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,608,590   26,993,131   128,149

     

    35.

    The resolution authorizing the Board of Directors to allocate for free existing and/or to be issued shares to employees and/or certain corporate officers of the Company or related companies or economic interest groups was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    163,776,980   26,880,444   72,446

     

    36.

    The resolution authorizing the Board of Directors to grant stock options to employees and/or certain officers of the Company or related companies or economic interest groups was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    171,812,106   18,843,706   74,058


    37.

    The resolution regarding the overall limit on the maximum authorized amounts set under the thirty-fifth and thirty-sixth resolutions was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    189,978,750   621,387   129,733

     

    38.

    The resolution ratifying the amendment to Article 18 and Article 21 of the Company’s bylaws was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    181,924,828   8,643,388   161,654

     

    39.

    The resolution regarding the amendment to Article 15 of the Company’s bylaws to set the age limit for the Chief Executive Officer at 70 years was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    175,397,495   15,184,713   147,662

    Within the authority of the Ordinary Shareholders’ Meeting:

     

    40.

    The resolution regarding powers to complete formalities was approved, based on the following votes:

     

    Voted For

     

    Voted Against

     

    Vote Withheld

    190,077,851   525,038   126,981

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.
      

    Description

    3.1    Amended and Restated By-laws (statuts) of DBV Technologies S.A. (English Translation)
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 3, 2026   DBV TECHNOLOGIES S.A.
        By:  

    /s/ Virginie Boucinha

        Name:   Virginie Boucinha
        Title:   Chief Financial Officer
    Get the next $DBVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DBVT

    DatePrice TargetRatingAnalyst
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    12/3/2025$35.00Buy
    Guggenheim
    5/29/2025$7.25Sell
    Goldman
    1/4/2023Hold → Buy
    Societe Generale
    12/16/2022Neutral → Sell
    Goldman
    5/10/2022$6.00 → $1.50Buy → Neutral
    Goldman
    12/21/2021$8.00 → $5.00Market Outperform
    JMP Securities
    12/21/2021$14.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date Total number of sharesTotal number of voting rights05/31/2026 296,061,497  Total gross of voting rights: 296,061,497  Total net* of voting rights: 295,906,088  * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

    6/3/26 4:31:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces the Results of its 2026 Combined General Meeting

    Châtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (TRQX:DBVp), a late stage biopharmaceutical company (the "Company"), held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Board of Directors (the "Board"). The Company's shareholders approved all resolutions submitted by the Board. The resolutions and voting results are posted on the Company's website: 2026 Annual General Meeting | DBV Technologies About DBV TechnologiesDBV Technologies is a late-stage biopharmaceutical company developing tre

    6/3/26 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

    Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergyFirst participant screened by Dr. Douglas Mack, Assistant Clinical Professor in the Department of Pediatrics at McMaster University, Ontario DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating

    6/2/26 7:40:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lee Philina

    3 - DBV Technologies S.A. (0001613780) (Issuer)

    4/16/26 4:51:42 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Mohideen Pharis sold $2,595 worth of Ordinary Shares (534 units at $4.86), decreasing direct ownership by 0.37% to 144,995 units (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/2/26 4:30:20 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    1/14/26 4:33:18 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    SEC Filings

    View All

    SEC Form 8-K filed by DBV Technologies S.A.

    8-K - DBV Technologies S.A. (0001613780) (Filer)

    6/3/26 4:05:31 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by DBV Technologies S.A.

    SCHEDULE 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    5/13/26 9:03:30 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by DBV Technologies S.A.

    SCHEDULE 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    5/13/26 7:00:03 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tasse Daniel bought $14,188 worth of Ordinary Shares (17,094 units at $0.83) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    3/11/24 4:15:38 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ndu Adora bought $1,624 worth of Ordinary Shares (1,825 units at $0.89) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/8/24 5:02:03 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on DBV Technologies with a new price target

    Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

    5/29/25 8:17:33 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Leadership Updates

    Live Leadership Updates

    View All

    DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

    Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026. "We are proud to be admitted into the CAC Mid 60 and SBF 120 Indices, which reflect the financial markets' recognition of our continued progress," stated Daniel Tassé, Chief Executive Officer of D

    3/24/26 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

    Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased

    10/30/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Financials

    Live finance-specific insights

    View All

    DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

    Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Safety results were consistent with the safety profile observed in the VIASKIN Peanut clinical program to dateBLA submission in 4-7-year-olds on track for the first half of 2026Achievement

    12/16/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

    Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

    6/25/25 4:15:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

    Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE    DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD

    1/8/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    2/14/24 8:56:45 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    2/14/24 4:06:12 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care